PARP1 and neoplasm: For instance, the hypermethylation of HR DNA repair genes BRCA1 and RAD51C (see above) have been documented in 35% of NSs, and these may possibly be used as biomarkers for sensitivity to PARP inhibitors [38], like in other tumor models [136].